Convatec Confirms Year-End Share Capital and Voting Rights

ConvaTec ( (GB:CTEC) ) has issued an announcement.

Convatec Group has disclosed its total voting rights as of 31 December 2025, reporting an issued share capital of 2,049,789,559 ordinary shares of 10 pence each, of which 94,937,530 are held in treasury without dividend or voting rights. This leaves 1,954,852,029 voting shares in circulation, a key reference figure for investors monitoring their holdings and regulatory disclosure thresholds under UK financial transparency rules, and it provides the market with clarity on the company’s capital structure at year-end.

The most recent analyst rating on (GB:CTEC) stock is a Buy with a £375.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.

Spark’s Take on GB:CTEC Stock

According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.

ConvaTec’s overall stock score is driven by strong financial performance and positive corporate events, particularly the share buyback program. However, technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued, which tempers the overall score.

To see Spark’s full report on GB:CTEC stock, click here.

More about ConvaTec

Convatec Group Plc is a global medical products and technologies company focused on managing chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. Operating in around 90 countries with more than 10,000 employees, the FTSE 100 constituent generates over $2 billion in annual revenue by offering solutions that support infection prevention, treatment of hard-to-heal wounds and at-risk skin, and improved patient outcomes alongside reduced care costs.

Average Trading Volume: 9,671,897

Technical Sentiment Signal: Strong Buy

Current Market Cap: £4.74B

See more data about CTEC stock on TipRanks’ Stock Analysis page.